NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / WHY: New York, N.Y., August 9, 2025. Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ:SLP) resulting from allegations that Simulations Plus may have issued materially misleading business […]

(NasdaqGM:ALT), NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Altimmune and certain of its officers and/or directors have engaged

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Altimmune, Inc. – ALT GlobeNewswire August 09, 2025 NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). Such investors are advised to contact Danielle Peyton at

(NYSE:DBI), NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Designer Brands Inc. (“Designer Brands” or the “Company”) (NYSE: DBI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Designer Brands and certain of its officers and/or

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Designer Brands Inc. – DBI GlobeNewswire August 09, 2025 NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Designer Brands Inc. (“Designer Brands” or the “Company”) (NYSE: DBI). Such investors are advised to contact

(NYSE:LMT), NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lockheed Martin Corporation (NYSE: LMT) between January 23, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 26, 2025 lead plaintiff deadline. SO WHAT: If

(NYSE:KBR), NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether KBR and certain of its officers and/or directors have engaged

(NASDAQ:EWTX), NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. (“Edgewise” or the “Company”) (NASDAQ: EWTX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Edgewise and certain of its officers and/or directors have

(NASDAQ:UNCY), NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Unicycive and certain of its officers and/or directors have

(NASDAQ:ARGX), NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of argenx SE (“argenx” or the “Company”) (NASDAQ: ARGX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether argenx and certain of its officers and/or directors have engaged